Abstract:Antibody fragments, as the products of engineered antibodies, exhibit great potential for cancer therapy and imaging. Antibody fragment drug conjugates (AFDCs), which conjugate the highly specific, low-immunity and small-sized antibody fragments with cytotoxic payloads, can overcome the limitations of traditional IgG format drugs in cancer therapy. In this study, a commercialized anti-CD20 monoclonal antibody, ofatumumab (OFA), was applied to generate two site-specific monomethyl auristain E (MMAE)-conjugated AFDCs (Fab-vcMMAE, Fab-CH3mut-vcMMAE) by Sortase A mediated transpeptidation. Compared with OFA-vcMMAE, the two AFDCs maintained most of the binding affinity and the ability of internalization. In vitro studies revealed that Fab-vcMMAE and OFA-vcMMAE had almost identical IC50 values against CD20-positive cell lines, while Fab-CH3-vcMMAE had a lower anti-tumor activity. In vivo studies showed that Fab-vcMMAE had a significantly higher maximum tolerated dose (MTDs), a 30-fold shorter half-life, and slightly lower antitumor activity within the MTDs than OFA-vcMMAE. The distribution study showed that both of the Fab and Fab-CH3mut had higher penetration rates into the tumors than OFA in a xenograft model. Additionally, no obvious difference in tumor drug accumulation was found between the Fab and OFA groups after the penetration process, but the Fab-CH3mut group exhibited less tumor drug accumulation, possibly contributing to the inferior anti-tumor activity of Fab-CH3mut-vcMMAE in vivo. Overall, we preliminarily demonstrated the characteristics of AFDCs by studying OFA-based AFDCs. Our results revealed that Fab is a promising carrier of MMAE to enhance the anti-tumor activity and increase the safety profile compared with OFA.

Development of a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF) for Targeted Antibody Blocking.

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF).

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Development of the Double Cyclic Peptide Ligand for Antibody Purification and Protein Detection.

Chemically Programmed Fc Protein As Antibody Mimetic to Targeting Carbonic Anhydrase IX

High Antitumor Activity of Sortase A-generated Anti-Cd20 Antibody Fragment Drug Conjugates

Development of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments

Rational Design of Potent Mimic Peptide Derived from Monoclonal Antibody: Antibody Mimic Design.

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Construction of a Versatile Fusion Protein for Targeted Therapy and Immunotherapy.

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Small Antibody Mimetics Comprising Two Complementarity-Determining Regions and a Framework Region for Tumor Targeting

Computational Design of an Epitope-Specific Keap1 Binding Antibody Using Hotspot Residues Grafting and CDR Loop Swapping

Engineering Antibody Fusion Proteins for Targeted Intracellular Therapeutic Delivery

Developing the IVIG Biomimetic, Hexa-Fc, for Drug and Vaccine Applications

T.129. Suppression of B Cell Activation by Inhibitory Receptor Signaling Using Dual-Affinity Re-Targeting (DART) Molecules

Conformation-reconstructed Multivalent Antibody Mimic for Amplified Mitigation of Human Islet Amyloid Polypeptide Amyloidogenesis.

Computational de novo design of antibodies binding to a peptide with high affinity.

Antibody–peptide conjugates for targeted inhibition of cysteine proteases

Design and assembly of anti-CD16 ScFv antibody with two different linker peptides.

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity